Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanidatamab zovodotin - Zymeworks

Next Previous
Drug Profile

Zanidatamab zovodotin - Zymeworks

Alternative Names: anti-HER2 x HER2 ADC - Zymeworks; ZW-49

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Gastric cancer; Solid tumours

Most Recent Events

  • 08 Oct 2024 Zymeworks BC completes phase-I trial in Solid-tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada, USA, Australia, South Korea (IV) (NCT03821233)
  • 21 May 2024 Zymeworks plans a phase II trial for zanidatamab zovodotin in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in 2024
  • 11 Oct 2023 Efficacy, adverse event, and pharmacokinetics data from a phase I trial in Oesophageal-cancer, Solid-tumours , and HER2-positive-breast-cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top